Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe's Annual Globe 100 List of Best Performing Companies
05.19.09 –
Cubist Lands Top Spot in First Appearance
Cubist 1Q09 Total Net Revenues Up 37%
04.21.09 –
Total Net Revenues $121.1 Million
Net Product Revenues $114.6 Million
CUBICIN's 2009 Net U.S. Revenue Guidance Reconfirmed at $520-540 Million
GAAP Basic and Diluted Net Income of $0.14 and $0.13 Per Share, Respectively
NON-GAAP Basic and Diluted Net Income of $0.47 and $0.42 Per Share, Respectively
GAAP Basic and Diluted Net Income of $0.14 and $0.13 Per Share, Respectively
NON-GAAP Basic and Diluted Net Income of $0.47 and $0.42 Per Share, Respectively
Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
03.27.09 –
Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc.
03.23.09 –
stories:
Cubist Pharmaceuticals, Inc. was ranked first among the "Top 100" Massachusetts-based publicly traded companies by The Boston Globe in its 21st annual "Globe 100" listing of 2009.
05.19.09 Read more,
watch video,
Boston Globe article.
Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Learn More »
| Last | 17.16 |
|---|---|
| Change |  0.60 |
| % Change | 3.38% |
| Bid | 17.16 |
| Bid Size | 200 |
| Ask | 18.15 |
Quotes Delayed At Least 20 Minutes
Cubist Investor Relations »
Next Earnings Call Information »
